🚀 VC round data is live in beta, check it out!
SOPHiA Genetics Valuation Multiples
Discover revenue and EBITDA valuation multiples for SOPHiA Genetics and similar public comparables like TaiDoc Technology, Medical Data Vision, National Research, Evolent Health and more.
SOPHiA Genetics Overview
About SOPHiA Genetics
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Founded
2011
HQ
Employees
423
Website
Financials (LTM)
EV
$371M
SOPHiA Genetics Financials
SOPHiA Genetics reported last 12-month revenue of $82M and negative EBITDA of ($39M).
In the same LTM period, SOPHiA Genetics generated $56M in gross profit, ($39M) in EBITDA losses, and had net loss of ($74M).
Revenue (LTM)
SOPHiA Genetics P&L
In the most recent fiscal year, SOPHiA Genetics reported revenue of $77M and EBITDA of ($42M).
SOPHiA Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $82M | XXX | $77M | XXX | XXX | XXX |
| Gross Profit | $56M | XXX | $52M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | ($39M) | XXX | ($42M) | XXX | XXX | XXX |
| EBITDA Margin | (47%) | XXX | (54%) | XXX | XXX | XXX |
| EBIT Margin | (82%) | XXX | (92%) | XXX | XXX | XXX |
| Net Profit | ($74M) | XXX | ($79M) | XXX | XXX | XXX |
| Net Margin | (90%) | XXX | (102%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SOPHiA Genetics Stock Performance
SOPHiA Genetics has current market cap of $378M, and enterprise value of $371M.
Market Cap Evolution
SOPHiA Genetics' stock price is $5.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $371M | $378M | 0.1% | XXX | XXX | XXX | $-1.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSOPHiA Genetics Valuation Multiples
SOPHiA Genetics trades at 4.5x EV/Revenue multiple, and (9.6x) EV/EBITDA.
EV / Revenue (LTM)
SOPHiA Genetics Financial Valuation Multiples
As of April 19, 2026, SOPHiA Genetics has market cap of $378M and EV of $371M.
Equity research analysts estimate SOPHiA Genetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SOPHiA Genetics has a P/E ratio of (5.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $378M | XXX | $378M | XXX | XXX | XXX |
| EV (current) | $371M | XXX | $371M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | (9.6x) | XXX | (8.9x) | XXX | XXX | XXX |
| EV/EBIT | (5.5x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | (5.1x) | XXX | (4.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SOPHiA Genetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SOPHiA Genetics Margins & Growth Rates
SOPHiA Genetics' revenue in the last 12 month grew by 20%.
SOPHiA Genetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
SOPHiA Genetics' rule of 40 is (14%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SOPHiA Genetics' rule of X is 17% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SOPHiA Genetics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | (47%) | XXX | (54%) | XXX | XXX | XXX |
| EBITDA Growth | (25%) | XXX | (21%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (14%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 64% | XXX | 68% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42% | XXX | 44% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 159% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SOPHiA Genetics Public Comps
See public comps and valuation multiples for other Health Data & Analytics and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SOPHiA Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiDoc Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Medical Data Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| National Research | XXX | XXX | XXX | XXX | XXX | XXX |
| Evolent Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogstate | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SOPHiA Genetics M&A Activity
SOPHiA Genetics acquired XXX companies to date.
Last acquisition by SOPHiA Genetics was on XXXXXXXX, XXXXX. SOPHiA Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SOPHiA Genetics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSOPHiA Genetics Investment Activity
SOPHiA Genetics invested in XXX companies to date.
SOPHiA Genetics made its latest investment on XXXXXXXX, XXXXX. SOPHiA Genetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SOPHiA Genetics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SOPHiA Genetics
| When was SOPHiA Genetics founded? | SOPHiA Genetics was founded in 2011. |
| Where is SOPHiA Genetics headquartered? | SOPHiA Genetics is headquartered in France. |
| How many employees does SOPHiA Genetics have? | As of today, SOPHiA Genetics has over 423 employees. |
| Who is the CEO of SOPHiA Genetics? | SOPHiA Genetics' CEO is Jurgi Camblong. |
| Is SOPHiA Genetics publicly listed? | Yes, SOPHiA Genetics is a public company listed on Nasdaq. |
| What is the stock symbol of SOPHiA Genetics? | SOPHiA Genetics trades under SOPH ticker. |
| When did SOPHiA Genetics go public? | SOPHiA Genetics went public in 2021. |
| Who are competitors of SOPHiA Genetics? | SOPHiA Genetics main competitors are TaiDoc Technology, Medical Data Vision, National Research, Evolent Health. |
| What is the current market cap of SOPHiA Genetics? | SOPHiA Genetics' current market cap is $378M. |
| What is the current revenue of SOPHiA Genetics? | SOPHiA Genetics' last 12 months revenue is $82M. |
| What is the current revenue growth of SOPHiA Genetics? | SOPHiA Genetics revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of SOPHiA Genetics? | Current revenue multiple of SOPHiA Genetics is 4.5x. |
| Is SOPHiA Genetics profitable? | No, SOPHiA Genetics is not profitable. |
| What is the current EBITDA of SOPHiA Genetics? | SOPHiA Genetics has negative EBITDA and is not profitable. |
| What is SOPHiA Genetics' EBITDA margin? | SOPHiA Genetics' last 12 months EBITDA margin is (47%). |
| What is the current EV/EBITDA multiple of SOPHiA Genetics? | Current EBITDA multiple of SOPHiA Genetics is (9.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.